Jane Street Group, LLC Vectiv Bio Holding Ag Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 14, 2023	SELL	$7.79 - $8.98 $36,426 - $41,990	-4,676 Reduced 19.56%	19,233 $166,000
Q3 2022 Nov 14, 2022	SELL	$4.7 - $6.07 $10,401 - $13,432	-2,213 Reduced 8.47%	23,909 $143,000
Q2 2022 Aug 16, 2022	SELL	$4.2 - $6.55 $126 - $196	-30 Reduced 0.11%	26,122 $141,000
Q1 2022 May 17, 2022	SELL	$4.6 - $5.8 $16,776 - $21,152	-3,647 Reduced 12.24%	26,152 $123,000
Q4 2021 Feb 15, 2022	SELL	$2.83 - $7.26 $59,591 - $152,873	-21,057 Reduced 41.41%	29,799 $146,000
Q3 2021 Nov 16, 2021	SELL	$6.7 - $11.54 $22,766 - $39,212	-3,398 Reduced 6.26%	50,856 $393,000
Q2 2021 Aug 16, 2021	BUY	$11.66 - $24.23 $632,601 - $1.31 Million	54,254 New	54,254 $633,000

Others Institutions Holding VECT

# of Institutions

1

Shares Held

510K

Call Options Held

0

Put Options Held

0

Regency Capital Management Inc.\De

510K
Shares

$0
0.0% of portfolio

About VectivBio Holding AG

Ticker VECT
Exchange NASDAQ
Description
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with sho...

More about VECT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.